What happened to the YSS?

Presenter: Richard Lucey, Jörg Faber
on behalf of EBF YSS

EBF 10th Open Meeting: 10 - A New Journey begins
15 Nov 2017
Barcelona
Outline

1) Introducing the EBF YSS
2) Previous three YSS events
3) The BioA Brain
1) Introducing YSS

- Young Scientist Symposium

- Early career bioanalytical scientists (typically < 35 or <5 years in bioanalysis) from industry (Pharma/CROs) or academia

- As a part of the EBF we also aim to:
  - Share, discuss, optimize and seek alignment on a broad array of bioanalytical topics (including science, procedures, business tools, technology, and regulatory issues)
Within the EBF:

- We contribute to the aim of recommending or influencing opinions/procedures towards our members, business partners, regulatory bodies and any other stakeholders

  - Going forward, EBF is providing guidance and recommendations to the European and Global bioanalytical community

- Provide development opportunities for EU based scientist by joining cross company collaborations and contributions to peer reviewed journals, international meetings and symposia
2) Previous three YSS events

1st YSS 2014 (Barcelona, Spain): “Unleashing the Future”

http://bcn2014.europeanbioanalysisforum.eu/YSS/

- 27 attendees
- 10 presenters
  (8 industrial, 2 academic)
- 7 posters
- Best poster prize
2) Previous three YSS events, cntd

2\textsuperscript{nd} YSS 2015 (Barcelona, Spain):
“Future of Bioanalysis… A Bridge between Industry and Academia”

- 51 attendees
- 22 presenters (20 industrial, 2 academic)
- 10 posters
- Best poster and best presenter prize
2) Previous three YSS events, cntd

3rd YSS 2016 (Barcelona, Spain):
“In Unity Lies Power; Building a Better Bioanalytical World Together”

Working together to win in the bioanalytical world, focusing on practical cases and new technologies

- 50 attendees
- 15 presenters (11 industrial, 4 academic)
- 7 posters
- Best presenter prize
EBF YSS standalone website since Sep 2017!

http://yss.europeanbioanalysisforum.eu/general/
...and a standalone meeting

The BioA Brain: Embracing New Ideas
15-16 March 2018 Ghent, Belgium (Het Pand)

- implementation of new technologies
- overcoming the challenges of working with novel therapeutics
1. **Automation**
   - Challenges and solutions of implementing automation into bioanalytical procedures

2. **Large / small molecule cross over**
   - Techniques for analysing both large and small molecules

3. **Increasing efficiencies**
   - Increasing productivity in day to day analysis

4. **Overcoming bioanalytical issues**

5. **Contending with new molecules and methods**
1. Automation

• Automation increases throughput and reproducibility but automation only does what it has been taught before
  ➢ Customization

• Are today’s platforms flexible enough to allow higher throughput or does adjustment time extend the benefit of automation?

• What about validation of automation? What exactly needs to be validated and how often should the validation be performed?

• Automation is our future and sometimes already our present
  ➢ we need a deep understanding of what should be automated and of the algorithms
2. Large / small molecule cross over

- What about LC-HRMS in quantitation assays? What are the benefits of HR and can we use them for quantitation of small and/or large molecules?

- Ligand-binding immunoassays ‘gold standard’ for bioanalysis in large molecule drug research, but they are time-consuming and costly.

- Can we use LC-MS/MS as potential alternative to or as complementary tool to immunoassays?

- How can we push state-of-the-art analysis, maintaining compliance with regulations?

- Are new technologies really a step forward?
3. Increasing efficiencies

- Increasing productivity in day to day analysis
  
  - standardising assay methods to work across multiple drug products
  
  - implementing more efficient techniques e.g. multi-analyte methods, streamline existing techniques
4. Overcoming analytical issues

• How have you successfully overcome problems in analysis?

➢ Achieving assay standards set out in regulatory guidelines
➢ Alternative and complementary techniques to overcome assay issues and/or data interpretation
➢ Overcoming limited sample volumes

Communicate and share experiences!
5. Contending with new molecules and methods

- ADCs,
- Nano-bodies
- Tand-antibodies
- Neutralising antibodies

- 2D-LC
- New microsampling and miniaturised pretreatment techniques
- Protein analysis by immunoprecipitation
- Micro/nanoflow LC
Abstract submission open

Speakers & Posters

**EBF Young Scientist Symposium**

If you plan to submit an abstract for oral presentation, click on [this link](http://www.europeanbioanalysisforum.eu/speakers/). The deadline for submission is 15 January 2018. We will inform you on the acceptance of your contribution before 22 January.

If you plan to submit an abstract for a poster, click on [this link](http://www.europeanbioanalysisforum.eu/speakers/). The deadline for submission is 19 February 2018. All posters will be accepted.
Meeting Organisation:

- Sheelan Ahmad (GlaxoSmithKline)
- Jörg Faber (A&M Labor)
- Godknows Hlatshwayo (MedImmune)
- Ariane Kahnt (Janssen R&D)
- Richard Lucey (LGC)
- Farjana Mahammed (GlaxoSmithKline)
- Cara Maguire (Charles River)
- Ryan McDonagh (Covance)
- Sufyan Maqbool (AstraZeneca)

Academic collaborators

- Sofie Velghe (Ghent University)
- Laura Mercolini (Uni of Bologna)
Thank you for listening